To build its contract manufacturing, Dr. Reddy's Laboratories (Hyderabad, India), one of India's largest pharmaceutical companies,
completed two key acquisitions in 2008: Dow Chemical's (Midland, MI) Dowpharma small-molecules business associated with its
Mirfield and Cambridge, England, sites, as well as BASF's (Ludwigshafen, Germany) manufacturing facility in Shreveport, Louisiana,
and related contract-manufacturing business for finished pharmaceuticals. Dr. Reddy's started building its custom manufacturing
business in the West in 2005 with the acquisition of a former Roche API manufacturing facility in Cuernavaca, Mexico.
Dishman Group (Ahmedabad, India), which acquired several Western firms over the past several years, is expanding. Dishman
bought the Swiss-based CMO Carbogen Amcis and I03S, a company specializing in ozone chemistry, in 2006, and the UK-based contract-research
company Synprotec in 2005. In 2007, Dishman acquired Solvay Pharmaceuticals' (Brussels) fine-chemicals and vitamin businesses,
which included facilities in The Netherlands, and the intellectual property rights for fine chemicals, vitamin D, and vitamin
Dishman announced capital investments of more than $33 million: $20 million in the current financial year and $13 million
planned for fiscal year 2009, which begins in April. Investments include the addition of a high-potency facility near Dishman's
headquarters in Bavla, India, and a new plant in Shanghai. The plant in Bavla will be managed and operated by the Dishman
subsidiary Carbogen Amcis, and is scheduled to be operational in mid-2009. The facility in Shanghai will include a production
plant, a warehouse, dedicated on-site utilities, and administrative and quality-control offices. Construction is underway
and is expected to be fully staffed and operational by the second quarter of 2009.
Drug, Chemical and Associated Technologies Association (DCAT): upcoming programs on pharma ingredients
CiVentiChem (Carey, NC), which was founded by scientists from Duke University as Universal Organics in the mid-1990s, provides
contract R&D services to pharmaceutical and biotechnology companies. It formed an Indian subsidiary, Indus BioSciences, approximately
six years ago in Hyderabad to provide research and development (R&D) services for those customers interested in having R&D
done in India. CiVentiChem recently expanded its capabilities in Cary, North Carolina, with the launch of a GMP analytical
laboratory to provide analytical services, and is building a pilot plant with 20,000-L capacity in Hyderabad to manufacture
large-volume intermediates and APIs.
Jubilant Organosys (Noida, Uttar Pradesh, India), made two key acquisitions to build its contract secondary manufacturing
activities: Hollister-Stier in 2007, which provided the company with US operations, and Draxis in 2008, which provided Canadian